Effects of Rituximab on the Development of Viral and Fungal Infections in Renal Transplant Recipients

Table 4

Risk factors for viral or fungal infection.

	% Infection	% Infection (Comparator)	Univariate; 𝑃 value	Odds ratio	Multivariate; 𝑃 value
Age ≥ 60 years	34	29 (<60 years)	0.39
Caucasian	30	30 (non-Caucasian)	0.98
Male gender	29	32 (female)	0.47
Diabetes history	35	27 (no diabetes)	0.08	1.2	0.47
History chronic virus	23	31 (no virus)	0.39
Deceased donor	38	18 (living donor)	<0.001	2.5	<0.001
Retransplant	30	30 (first transplant)	0.98
Kidney-pancreas recipient	58	28 (kidney only)	<0.001	1.7	0.22
Perioperative ATG	32	27 (no ATG)	0.33
Steroids at discharge	30	30 (steroid withdrawal)	0.90
Delayed graft function	34	30 (initial function)	0.54
Acute rejection	43	27 (no rejection)	0.007	1.5	0.12
ATG for rejection	34	30 (no ATG)	0.58
Any ATG exposure	32	27 (no ATG exposure)	0.31
Any RTX exposure	47	28 (no RTX exposure)	0.005	2.2	0.016

Abbreviations—ATG: antithymocyte globulin; RTX: rituximab.